Ophthalmology is a broad therapy area that consists of almost 100 disorders associated with the eyes and visual system, including such diseases as glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and dry eye syndrome (DES). Many of these disorders are progressive, and if left untreated can lead to severe visual impairment or even blindness.
Of the five key indications within the therapy area - glaucoma, AMD, DME, DR and DES - glaucoma and AMD have the most active product pipelines.
In 2018, the global Ophthalmology Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Ophthalmology Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Ophthalmology Drugs development in United States, Europe and China.
The key players covered in this study
Market segment by Type, the product can be split into
Alphagan (Brimonidine Tartrate)
Market segment by Application, split into
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Ophthalmology Drugs status, future forecast, growth opportunity, key market and key players.
To present the Ophthalmology Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Ophthalmology Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.